Temperament profiles, major depression, and response to treatment with SSRIs in psychiatric outpatients

Eur Psychiatry. 2012 May;27(4):245-9. doi: 10.1016/j.eurpsy.2010.07.006. Epub 2010 Oct 8.

Abstract

Objective: The Temperament and Character Inventory (TCI) is commonly used in adult populations. Our aim was to explore: (1) if there are specific differences in temperament dimensions related to depression in comparison with general population, (2) if the treatment response during the acute phase of major depressive disorder (MDD) is predictable by TCI temperament dimensions.

Method: Temperament profiles in 98 MDD patients were compared with a Finnish community sample. The patients were treated with serotonin selective reuptake inhibitors (SSRIs) for 6 weeks and their temperament profiles were assessed at baseline and endpoint. The harm avoidance (HA) and depression scores at baseline and endpoint were modelled with path analysis. For path modelling, we tested the relationships between different temperament dimensions and depression symptoms and other clinical variables with Mancova model.

Results: The HA scores were significantly higher in patients both at baseline and endpoint compared to the Northern Finland 1966 Birth Cohort (NFBC). The patients, and especially males, had slightly higher reward dependency (RD) scores. HA at endpoint explained moderately the Montgomery Åsberg Depression Rating Scale (MADRS) endpoint score. HA endpoint score was strongly explained by HA baseline score.

Conclusions: HA is associated with risk of and treatment response to depression.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antidepressive Agents / therapeutic use*
  • Depressive Disorder, Major / drug therapy*
  • Depressive Disorder, Major / psychology*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Outpatients / psychology*
  • Personality Inventory
  • Risk
  • Selective Serotonin Reuptake Inhibitors / therapeutic use*
  • Temperament*

Substances

  • Antidepressive Agents
  • Serotonin Uptake Inhibitors